LakeShore Biopharma (LSB) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LakeShore Biopharma has announced significant leadership changes, appointing Xu Wang as the new CEO and Dr. Hui Shao as both the Chief Business Officer and Vice Chairman of the Board. Further consolidating its management team, Rachel Yu has been named the permanent Chief Financial Officer. These strategic appointments, effective from September 1, 2024, are aimed to reinforce the company’s commitment to advancing biopharmaceuticals for infectious diseases and cancer.
For further insights into LSB stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue